Have the markets overreacted to bad guidance? When a stock falls more than 40% on a single day, as DexCom did due to underwhelming guidance, it's hard to not call that an overreaction in the markets.

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

Management maintained its full-year guidance for $4 billion to $4.05 billion in revenue. DexCom experienced slower growth and profitability challenges, but still met management's expectations for ...

In March, the FDA cleared Dexcom’s Stelo, making it the first ... showing when users’ glucose levels spike and ebb throughout the day. “When someone sees their own personal data, that ...

Over the past five years, diabetes-focused medical device specialist DexCom (NASDAQ ... blood glucose levels efficiently throughout the day, has been linked with better outcomes.

Shares of DexCom Inc. DXCM shed 1.88% to $73.44 Friday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.03% to 5,808.12 and Dow ...

Dexcom enjoys a well-established track record ... meters that typically provided two to four blood glucose readings in a day for Type 2 patients. It also ties the CGM much more closely with ...

Here's why you should take advantage. DexCom ( NASDAQ:DXCM ) Third Quarter 2024 Results Key Financial Results Revenue: US$994.2m (up 2.0% from 3Q 2023). Net... Dexcom stock closed in the red on ...

With a market cap of $27.1 billion, DexCom, Inc. (DXCM) is a leading medical device company, specializing in continuous glucose monitoring (CGM) systems for diabetes management. The San Diego ...

Following the completion of the necessary clinical work, we submitted our DexCom G7 15-day CGM system to the FDA for review. This has been a top priority across the organization and we're looking ...